A Democratic group is launching $2 million in new digital ads highlighting vulnerable House Democrats’ efforts to lower drug prices. 

The ads from the group Protect Our Care illustrate how Democrats are seeking to keep their momentum going on health care after they focused on the issue in winning back the House last year.

ADVERTISEMENT

The ad buy shows that even as the impeachment inquiry into President TrumpDonald John TrumpTrump reversed course on flavored e-cigarette ban over fear of job losses: report Trump to award National Medal of Arts to actor Jon Voight Sondland notified Trump officials of investigation push ahead of Ukraine call: report MORE gains focus, Democrats are still trying to focus on kitchen-table issues like lowering drug prices. 

The new spending will bring the ads to 10 new districts of House freshmen, on top of the 10 districts that were part of an earlier $2 million-buy in September focused on pre-existing conditions. 

“Representative Elissa SlotkinElissa SlotkinOvernight Health Care: Walden won’t seek reelection | Senate Dems to vote this week to overturn Trump ObamaCare moves | Largest children’s migrant shelter to close | Vulnerable Republicans balk at drug pricing bill House passes third bill aimed at preventing foreign election interference Avoiding the snake in the grass: Let’s not allow impeachment to divide us MORE [D-Mich.] is standing up to big drug companies,” the narrator in the ad for Slotkin, a Michigan Democrat, states. “She’s fighting to give Medicare the power to negotiate with drug companies for lower prices, reducing your costs by as much as 55 percent.”

Click Here: Cheap Golf Golf Clubs

“Thank her for leading the fight to lower your drug prices,” it adds.

The 10 new districts in the campaign are those of Democratic Reps. Angie Craig (Minn.), Sharice DavidsSharice DavidsWarren doubles down — to Democrats’ chagrin, and Trump’s delight Here are the Democrats who aren’t co-sponsoring an assault weapons ban Centrist House Democrats press for committees to follow pay-go rule MORE (Kan.), Antonio DelgadoAntonio Ramon DelgadoProgressive Latino group launches first incumbent protection campaign Trump impeachment battle hits TV ads Pelosi-backed group funding ads for vulnerable Democrats amid impeachment inquiry MORE (N.Y.), Lizzie Fletcher (Texas), Jared Golden (Maine), Susie LeeSuzanne (Susie) Kelley LeeMORE (Nev.), Elaine LuriaElaine Goodman LuriaLawmakers under pressure to pass benefits fix for military families Pelosi-backed group funding ads for vulnerable Democrats amid impeachment inquiry Mass shootings have hit 158 House districts so far this year MORE (Va.), Lucy McBathLucia (Lucy) Kay McBathDemocrats will win back the Senate majority in 2020, all thanks to President Trump How centrist Dems learned to stop worrying and love impeachment DACA student at Yale petitions to protect mother recovering with cancer from deportation MORE (Ga.), Chris PappasChristopher (Chris) Charles PappasPelosi-backed group funding ads for vulnerable Democrats amid impeachment inquiry Lawmakers beat reporters in annual spelling bee competition The Hill’s Morning Report – US coastline readies for Hurricane Dorian to make landfall MORE (N.H.) and Susan WildSusan WildOvernight Defense: Protests at Trump’s NYC Veterans Day speech | House Dems release Pentagon official’s deposition transcript | Lawmakers ask Trump to rescind Erdogan invite Bipartisan House members call on Trump to rescind Erdoğan invitation The Hill’s Morning Report – Congress returns: What to expect MORE (Pa.), all of whom face potentially tough reelection races next year. 

House Democrats are planning to vote next month on their signature legislation to lower drug prices, known as H.R. 3, which would empower the Secretary of Health and Human Services to negotiate lower prices for up to 250 drugs per year. 

Speaker Nancy PelosiNancy PelosiSchumer calls on Trump to testify as part of impeachment inquiry Sunday shows — Spotlight shifts to Sondland ahead of impeachment inquiry testimony Perception won’t be reality, once AI can manipulate what we see MORE’s (D-Calif.) office has expressed hope that President Trump would back the legislation, given his support for Medicare negotiating drug prices during the 2016 campaign. But Trump backed off that support in office, and the White House has recently criticized Pelosi’s bill, in favor of a somewhat more modest bipartisan measure to lower drug prices in the Senate. 

Republicans warn Pelosi’s bill would hinder the development of new cures. 

“We don’t see that happening,” Protect Our Care Chair Leslie Dach said of GOP support for the bill.

“Every statement from the president is that he opposes it,” he added. 

Campaigning on the issue could still prove effective for Democrats given the priority the public places on lowering drug prices. 

Dach said the ads are to “be sure [House Democrats] get thanked and be sure their constituents know they’re doing it.”